Prexasertib-d4

• Description :

  Prexasertib-d4 (LY2606368-d4) is the deuterium labeled Prexasertib (HY-18174) . Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of 50=8 nM) and RSK1 (IC50=9 nM) . Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity[1][2].

• Product Name Alternative :

  LY2606368-d4

• UNSPSC :

  12352005

• Target :

  Apoptosis; Checkpoint Kinase (Chk) ; Isotope-Labeled Compounds

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Others

• Field of Research :

  Cancer

• Smiles :

  NC([2H])([2H])CC([2H])([2H])OC(C=CC=C1OC)=C1C2=CC(NC3=NC=C(C#N)N=C3)=NN2

• Molecular Formula :

  C18H15D4N7O2

• Molecular Weight :

  369.41

• References & Citations :

  [1]King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14 (9) :2004-1|[2]Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7 (3) :473-483.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported